Juan Francisco Rodríguez-Moreno

5PUBLICATIONS
56CO-AUTHORS
Predictive and prognostic markersNanomedicineMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 27, 2026
Epidemiology, Comorbidities and Associated Treatments, Therapeutic Management, and Clinical Outcomes in Patients with Prostate Cancer in Spain (SRealProstate): A Real-World Cohort Study.

Angel Borque-Fernando, Nuria Romero-Laorden, Juan Francisco Rodríguez-Moreno

|Jun 27, 2025
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag

|Apr 29, 2025
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

Juan F Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández

|Apr 02, 2024
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.

Adam J Schoenfeld, Sylvia M Lee, Bernard Doger de Spéville

|Jul 26, 2022
Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.

Daniel Herrero Rivera, Carmen Garrigós Vacas, Laura Marcos Kovandzic

Pageof 1

Frequent Collaborators

2 joint publications

Cristina Rodríguez-Antona

1 joint publications

Daniel Herrero Rivera

1 joint publications

Carmen Garrigós Vacas

1 joint publications

Javier Puente Vázquez